15862-23-4

Basic information

• Product Name: [3,3'-BIPYRIDIN]-5-OL
• Synonyms: [3,3']BIPYRIDINYL-5-OL;[3,3'-BIPYRIDIN]-5-OL
• CAS NO: 15862-23-4
• Molecular Formula: C10H8N2O
• Molecular Weight: 172.18
• Mol File: 15862-23-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [3,3'-BIPYRIDIN]-5-OL(CAS DataBase Reference)
• NIST Chemistry Reference: [3,3'-BIPYRIDIN]-5-OL(15862-23-4)
• EPA Substance Registry System: [3,3'-BIPYRIDIN]-5-OL(15862-23-4)

Safety Data

• Hazardous Substances Data: 15862-23-4(Hazardous Substances Data)

Upstream product

• 883872-74-0 5-benzyloxy-[3,3']bipyridinyl 
• 74115-12-1 5-chloropyridin-3-ol 
• 1692-25-7 3-pyridylboronic acid 

Relevant articles and documents

COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES

Disclosed herein are compounds and compositions for modulating glycolate oxidase, useful for treating oxalate-related diseases, such as hyperoxaluria, where modulating glycolate oxidase is expected to be therapeutic to a patent in need thereof. Methods of modulating glycolate oxidase activity in a human or animal subject is also provided.

A versatile method for suzuki cross-coupling reactions of nitrogen heterocycles

(Chemical Equation Presented) A wide-ranging study of Suzuki reactions which use nitrogen-containing heterocycles is described (see scheme; dba = dibenzylideneacetone, Cy = cyclohexyl). This method is highly versatile (a single procedure was used for all substrates, including boronate esters and trifluoroborates), compatible with a variety of unprotected functionalities (e.g., NH2-and OH-substituted substrates), and efficient even with unactivated aryl chlorides.

BIPYRIDYL AMINES AND ETHERS AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5

The present invention is directed to novel bipyridyl amine and ether compounds such as those of Formula (I): (I) (where R?1#191, R?2#191, R?3#191, X and Y are as defined herein) which are mGluR5 modulators useful in the treatment or prevention of diseases and conditions in which mGluR5 is involved, including but not limited to psychiatric and mood disorders such as schizophrenia, anxiety, depression, bipolar disorders, and panic, as well as in the treatment of pain, Parkinson’s disease, cognitive dysfunction, epilepsy, circadian rhythm and sleep disorders, such as shift-work induced sleep disorder and jet-lag, drug addiction, drug abuse, drug withdrawal, obesity and other diseases. The invention is also directed to pharmaceutical compositions comprising these compounds. This invention further provides a method of treatment of these disorders and conditions by the administration of an effective amount of these novel bipyridyl amine and/or ether compounds and/or compositions containing these compounds.